Presidio Partners, a venture capital firm based in San Francisco, invests in IT, life sciences, and energy technology companies.
Business Model:
Revenue: $111.8k
Employees: 2-10
Address: 1 Letterman Dr
City: San Francisco
State: CA
Zip: 94129
Country: US
Previously known as [CMEA Capital](https://www.crunchbase.com/organization/cmea-capital/description/edit), Presidio Partners leverages the deep sector experience and learnings that they have gained through our 25+ years in venture capital as CMEA Capital. In addition, they have added a number of new capabilities that we believe are critical, including active portfolio management and a focus on company-building throughout the duration of our investment. They seek to embrace change and creativity to improve outcomes because that is what they believe it will take to successfully tackle the business challenges of the coming decade. Presidio Partners experiments with novel approaches to pharmaceutical development that they believe may increase efficiency. They rethink our portfolio companies’ approaches, and seek to develop new business models where appropriate. The entire Presidio team believes in the power of technology and data to push their entrepreneurs and themselves in ways that will make the world a better place and help us meet ever-changing societal challenges.
Contact Phone:
+14153521520
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
5/2012 | Inventure Chemicals | Venture Round | 5M |
4/2015 | Cnano Technology | Series B | 0 |
7/2011 | SurgiQuest | Series C | 19M |
2/2017 | Mojo Networks | Series E | 0 |
10/2019 | ESS | Series C | 0 |
12/2017 | ESS | Series B | 0 |
12/2012 | SurgiQuest | Series D | 0 |
1/2004 | Marathon Technologies | Venture Round | 8.8M |
1/2018 | Solaria | Venture Round | 0 |
10/2010 | Auspex Pharmaceuticals | Series C | 12M |
7/2017 | VYNE Therapeutics | Series C | 50.5M |
1/2014 | Auspex Pharmaceuticals | Series E | 0 |
11/2015 | VYNE Therapeutics | Series B | 45M |
3/2005 | Nominum | Series D | 16M |
7/2014 | BlueStacks | Series B | 0 |
10/2019 | Wildcat Discovery Technologies | Series C | 0 |
2/2015 | Neos Therapeutics | Venture Round | 20.6M |
1/2001 | Ensim Corporation | Venture Round | 0 |
10/2019 | ESS | Series C | 0 |
10/2019 | Wildcat Discovery Technologies | Series C | 0 |
1/2018 | Solaria | Venture Round | 0 |
12/2017 | ESS | Series B | 0 |
7/2017 | VYNE Therapeutics | Series C | 0 |
2/2017 | Mojo Networks | Series E | 0 |
11/2015 | VYNE Therapeutics | Series B | 0 |
4/2015 | Cnano Technology | Series B | 0 |
2/2015 | Neos Therapeutics | Venture Round | 0 |
7/2014 | BlueStacks | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|